We are live on !
Find out more
Stonepine Capital Management Portfolio holdings
AUM
$177M
Turnover
41.12%
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.68%
10 Year Est. Return
+2,169.51%
AUM
$177M
AUM Growth
-$72.5M
(-29%)
Cap. Flow
+$12.6M
Cap. Flow % of AUM
Cap. Flow %
7.11%
Top 10 Holdings %
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.7
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eloxx Pharmaceuticals
ELOX
|
+$5.07M |
| 2 |
Edesa Biotech
EDSA
|
+$3.85M |
| 3 |
SUPN
Supernus, Inc. Common Stock
SUPN
|
+$3.63M |
| 4 |
Cabaletta Bio
CABA
|
+$2.85M |
| 5 |
Satellos Bioscience
MSLE
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenax Therapeutics
TENX
|
+$4.03M |
| 2 |
Zevra Therapeutics
ZVRA
|
+$2.46M |
| 3 |
Xoma
XOMA
|
+$2.18M |
| 4 |
Abeona Therapeutics
ABEO
|
+$1.04M |
| 5 |
Inhibikase Therapeutics
IKT
|
+$1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.11% |
| 2 | Miscellaneous | 25.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Surrozen
SRZN
$364M
| – | – |
-33,005
| Closed | -$961K | – |
|
102
CALL
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-100,000
| Closed | -$5.27M | – |
|
103
Verrica Pharmaceuticals
VRCA
$54.8M
| – | – |
-99,735
| Closed | -$528K | – |
|
104
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| – | – |
-400,000
| Closed | -$51.1M | – |
|
|
105
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| – | – |
-400,000
| Closed | -$51.1M | – |
|
106
Xeris Biopharma Holdings
XERS
$2.78B
| – | – |
-40,030
| Closed | -$256K | – |
|
|
107
DELISTED
Xoma
XOMA
| – | – |
-69,500
| Closed | -$2.18M | – |
|
Similar funds
CMP
CCM
Stonepine Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.
- Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
- Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
- Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
- Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
- Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
- Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
- Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.
Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.